Yuval Horn, Shimrit Roznek and Yael Bar Hillel represented Metabomed Ltd. in its Asset Purchase Agreement with EpiVario Inc., for the sale of Metabomed’s small molecule acetyl co-A synthetase-2 inhibitor portfolio.
January 24, 2024
Yuval Horn, Yonatan Levinstein & Tal Gazanda represented Prisma Photonics in the Series C Investment agreement with IEC.
December 20, 2023
Despite the times, Yuval Horn Co-moderated a panel about #AI and Medical Devices at the #IBA Annual Conference in Paris.
November 2, 2023
Congratulations to our client, Biosight Ltd. on completing the merger with Ayala Pharmaceuticals, Inc. Yuval Horn, Assaf Unger and Ana Eiskov represented Biosight, together with Mayan Katz of Goodwin.
October 22, 2023
Congratulations to our client, Vascular Biogenics Ltd. (Nasdaq: VBLT) on completing the merger with Notable Labs and the sale of its IP assets. VBL was represented by Horn & Co. (Yuval Horn, Shimrit Roznek, Roy Ribon, Yael Bar-Hillel and Shai Perel) and by Goodwin.
October 19, 2023
Yuval Horn, Assaf Unger, Ana Eiskov and Shiran Glantz represent Biosight Ltd. in the merger agreement with Ayala Pharmaceuticals, Inc.
July 31, 2023
Yuval Horn, Assaf Unger, Ana Eiskov and Revital Guttman represented our client, INX, in its investment and collaboration transactions with Republic
June 25, 2023
Yuval Horn Co-chaired the IBA 9th Annual World Life Sciences Conference in Washington.
June 2, 2023
Keren Kanir, Yuval Horn and Danielle Wassner represented Scopio Labs in its collaboration agreement with Siemens Healthineers to Distribute Full-Field Digital Cell Morphology Technology
May 10, 2023
Uri Dotan and Shira Brami represented Vidac Pharma Ltd. in the registration of Its securities on the Hamburg Stock Exchange
April 5, 2023
